// App-Quantinova.ai

e11588 : A nonrandomized phase II study of dose-dense paclitaxel and cyclophosphamide (PC) in early-stage breast cancer (EBC).

Researchers

Presenter

  • Kailash Mosalpuria

Principal Investigators

  • Ryan C. Ramaekers

  • Elizabeth Lyden

  • Wajeeha Razaq

  • Elizabeth C. Reed

  • Mehmet Sitki Copur

  • Kenneth H. Cowan

  • Mary Mailliard

Medical Centers

  • St. Francis Medical Center, Grand Island, NE

  • Central Care Cancer Center, Emporia, KSUniversity of Nebraska Medical Center, Omaha, NEUniversity of Nebraska College of Medicine, Omaha, NE

  • Eppley Cancer Institute, University of Nebraska, Omaha, NE

  • Saint Francis Cancer Treatment Center, Grand Island, NE

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pegfilgrastim

  • Trastuzumab

  • Paclitaxel

Outcome

  • Positive

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01106898

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved